Teva ‘well positioned for upside from here,’ says JPMorgan

JPMorgan sees an “increasingly interesting setup” with Teva (TEVA) shares. In the near-term, the company’s $700M cost cutting program should enable “healthy” margin expansion despite the upcoming generic Revlimid headwind, the analyst tells investors in a research note. Looking into 2027 and beyond, JPMorgan sees a “long runway for growth,” driven by Teva’s branded pharma business, which it says includes several multi-billion assets including Austedo, olanzapine, and Duvakitug. With the shares trading at less than 7-times estimated 2025 earnings, and increasing capital allocation flexibility, Teva “appears well positioned for upside from here,” says JPMorgan.